HuidaGene and Synthego Announce Licensing Agreement on Next-Generation Gene Editing Enzyme, hfCas12Max
- Written by PR Newswire
SHANGHAI and REDWOOD CITY, Calif. , May 29, 2024 /PRNewswire/ -- HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company focused on advancing CRISPR-based genomic medicines, and Synthego Corporation ("Synthego"), a leading provider of innovative CRISPR solutions for developing cell and gene therapies, proudly...
